How Peptides Are Made: Solid-Phase Synthesis in Plain English

The basic idea

Solid-phase peptide synthesis, developed by Bruce Merrifield and recognised with a Nobel Prize in 1984, anchors the first amino acid to an insoluble resin bead and builds the chain outward one residue at a time.

Each cycle is the same: remove the protecting group from the growing chain, wash, couple the next protected amino acid, wash. Because the product stays bound to the resin, purification between steps is simply rinsing — which is what makes automation possible.

Why length is expensive

Coupling efficiency is high but not perfect. At 99 percent per step, a fifteen-residue peptide finishes at 0.99^14, about 87 percent of chains intact. At 98 percent it drops to roughly 75 percent. At 95 percent, under half.

The shortfall is not waste — it is deletion sequences, chains missing one or more residues, which are chemically similar to the target and therefore hard to separate. This is the main reason long peptides cost disproportionately more and why yields fall as length rises.

Cleavage and purification

When the sequence is complete, the peptide is cleaved from the resin and side-chain protecting groups are removed, commonly with trifluoroacetic acid plus scavengers that mop up reactive fragments.

The crude product then goes through preparative reversed-phase HPLC. Purity above 95 percent generally means this has been done properly; crude peptide straight off the resin is a different grade of material entirely.

The impurities you should expect

Deletion sequences missing a residue. Truncated sequences that stopped early. Incompletely deprotected chains. Oxidised methionine or tryptophan. Racemised residues where stereochemistry inverted during coupling. Residual TFA from cleavage and purification. Residual solvents such as DMF and acetonitrile.

These are known, characterised and testable. A manufacturer that can tell you its impurity profile is one that has looked.

What this implies for sourcing

Synthesis quality varies enormously and is invisible in the finished capsule. Two products naming the same peptide can contain materially different material.

The questions that separate them: what purity specification, measured by what method, with what impurity profile, and is there lot-level documentation. These are answerable, and the answers differentiate suppliers more than any label design.